Second Sight Medical Products Stock News

A 1-for-3 reverse split of Second Sight Medical Products (EYES) has gone into effect. These are the details.

Gainers Qudian Inc. (NYSE: QD) rose 61.3% to $1.92 in pre-market trading after the company issued an update on its QD Food ready-to-cook meal business. AMTD Digital Inc. (NYSE: HKD) rose 40% to $22.

The Federal Open Market Committee opted to raise fed funds rates by 0.75% on Wednesday to a new target range of between 1.5% and 1.75%. Investors, meanwhile, focused on some notable insider trades. Wh

US crude oil futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern

US stock futures traded higher on Thursday, with the Dow futures adding more than 200 points this morning. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell

A patient with the Argus II. | Photo by Dunyagoz Hospital/Anadolu Agency/Getty Images More than 350 blind people around the world have implants in their eyes made by the company Second Sight Medical Products , which could help partially restore aspects of sight. But the company abandoned the technology a few years ago when it was teetering on the verge of bankruptcy, according to a new investigation from IEEE Spectrum . Now, if something goes wrong with the implants, users are left stranded. “It is fantastic technology and a lousy company,” Ross Doerr, a Second Sight patient, told IEEE Spectrum . Second Sight’s implants, the Argus I and the Argus II, don’t restore normal vision; people see things in shades of gray that disappear when they move their heads. And results vary from person to person. Some users of the implants, which rolled out a decade ago, have struggled to make out even basic shapes. Others are now able to do things like ski. People who received the implants were told that there would be future updates and improvements to the technology, like software updates to boost the number of pixels in the system and thermal imaging, IEEE Spectrum reported this week.

Haemonetics HAE +13%. Second Sight Medical Products EYES +8%. Pulse Biosciences (PLSE) -36%. Karyopharm Therapeutics KPTI -22%.

What you need to know about trading penny stocks on February 8th The post Trading Penny Stocks? Top Stock Market News For February 8th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Info

Second Sight Medical Products Inc (NASDAQ: EYES ) will acquire privately-held Nano Precision Medical Inc in an all-stock transaction . Second Sight Medical develops implantable visual prosthetics. Under the agreement, Nano Precision Medical will merge with a wholly-owned subsidiary of Second Sight . The surviving company Nano Precision Medical will be owned by Second Sight. The newly-formed merged company will focus on developing innovative implants Full story available on Benzinga.com

What you need to know about trading penny stocks on February 8th The post Trading Penny Stocks? Top Stock Market News For February 8th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Info

Second Sight Medical Products Inc (NASDAQ: EYES) will acquire privately-held Nano Precision Medical Inc in an all-stock transaction.  Second Sight Medical develops implantable visual prosthetics.

Second Sight Medical Products (EYES) will acquire Nano Precision Medical (NPM) and merge it with a wholly-owned subsidiary in an all-stock transaction.EYES will issue ~134M shares…

LOS ANGELES & EMERYVILLE, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”) and Nano Precision Medical, Inc. (“NPM”), today announced that they have entered into a definitive agreement under which privately held NPM will merge with a wholly owned subsidiary of Second Sight in an all-stock transaction. NPM will be the surviving company and owned by Second Sight. The resulting company will focus on development of innovative drug and devi

CONMED (NYSE:CNMD) and Second Sight Medical Products (NASDAQ:EYES) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings. Analyst Recommendations This is a summary of recent ratings for CONMED and Second Sight Medical []